BrainStorm regains Nasdaq minimum bid price compliance; listing continues

BRAINSTORM CELL THERAPEUTICS INC.

Received Nasdaq notice of compliance on Oct 29, 2024; common stock continues on Nasdaq Capital Market.
Effected 1-for-15 reverse stock split on Sep 30, 2024 to regain compliance.
Stock closed above $1.00 for ten consecutive trading days as of Oct 15, 2024.
Previously faced delisting; Nasdaq hearing panel granted temporary exception until Oct 21, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.